磁共振引导经尿道超声消融治疗良性前列腺梗阻:II期研究1年临床结果
这项前瞻性单中心早期II期研究纳入30例计划行经尿道前列腺电切术的良性前列腺梗阻(BPO)患者,评估MRI引导经尿道超声消融(TULSA)的安全性与疗效。12个月随访显示前列腺体积、PSA、排尿功能及生活质量均显著改善,性功能稳定或改善,不良事件均可缓解,但指南尚未推荐且需长期验证。
要点
- TULSA术后12个月IPSS从17降至4,QoL从4降至1,最大尿流率从11.1升至18.3 mL/s。
- 前列腺体积中位数从52降至32 mL,PSA从3.1降至1.5 μg/L。
- 13例不良事件中11例为II级(尿路感染/尿潴留),1例IIIb级(附睾炎需全麻下引流),均缓解。
核心结论
- TULSA对BPO患者12个月时尿路功能和生活质量有临床显著改善,并保留控尿和性功能。
- TULSA目前仍为实验性治疗,指南尚未推荐,需长期结局和更大队列验证。
研究设计与样本
- 前瞻性、单中心、早期II期研究(NCT03350529),纳入30例计划行初次经尿道前列腺电切术的BPO男性。
- 12个月内以基线及每3个月评估尿流率、PSA和 validated 问卷,基线与3、12个月行MRI。
- 不良事件按Clavien-Dindo分级记录。
主要发现
- 治疗时中位年龄67岁;12个月随访中前列腺体积中位数从52降至32 mL,PSA从3.1降至1.5 μg/L。
- 最大尿流率从11.1升至18.3 mL/s(P < 0.001),平均尿流率从4.2升至9.1 mL/s(P < 0.001)。
- 残余尿量从71降至40 mL,排尿量从211升至301 mL。
- IPSS从17降至4(P < 0.001),IPSS生活质量评分从4改善至1(P < 0.001)。
- 26项扩展前列腺癌指数复合泌尿刺激/梗阻评分从66改善至94(P < 0.001),尿失禁评分从86改善至100(P = 0.008),性功能稳定或改善。
关键数值与推荐
- 共记录13例不良事件:11例II级(尿路感染/尿潴留)和1例IIIb级(附睾炎需全麻下引流),所有不良事件随访期间缓解。
临床怎么用
- TULSA可作为BPO的微创实验性选择,12个月时改善排尿症状和生活质量并保留控尿与性功能。
- 因指南未推荐且缺乏长期数据,临床应用应限于研究或充分知情选择,并强调长期随访。
局限性
- 单中心、早期II期、样本量30例,结果需更大队列验证。
- 随访仅12个月,长期疗效与安全性未确定。
- 指南尚未推荐TULSA用于BPO。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the safety and efficacy of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) as a minimally invasive alternative for benign prostatic obstruction (BPO). PATIENTS AND METHODS: This prospective, single-centre, early phase II study (NCT03350529) included 30 men with BPO scheduled for primary transurethral resection of the prostate. Assessments over 12 months included uroflowmetry, prostate-specific antigen (PSA) levels, and validated questionnaires at baseline and 3-month intervals. MRI was performed at baseline and at 3 and 12 months. Medication use and adverse events (AEs) were recorded and graded using the Clavien-Dindo classification. RESULTS: The median patient age at treatment was 67 years. During the 12-month post-TULSA follow-up, prostate volume decreased from a median of 52 to 32 mL, and PSA levels from 3.1 to 1.5 μg/L. The maximum flow rate increased from 11.1 to 18.3 mL/s (P < 0.001), and the average flow rate from 4.2 to 9.1 mL/s (P < 0.001). Residual volume decreased from 71 to 40 mL, and voided volume increased from 211 to 301 mL. The International Prostate Symptom Score (IPSS) decreased from 17 to 4 (P < 0.001), and IPSS quality of life score improved from 4 to 1 (P < 0.001). The 26-item Expanded Prostate Cancer Index Composite urinary irritative/obstructive scores improved from 66 to 94 (P < 0.001), and urinary incontinence scores improved from 86 to 100 (P = 0.008). Sexual function remained stable or improved. A total of 13 AEs were recorded, including 11 Grade II events (urinary tract infections/retentions) and one Grade IIIb event (epididymitis requiring drainage under general anaesthesia). All AEs resolved during follow-up. CONCLUSIONS: Transurethral ultrasound ablation appears to be a safe and effective experimental treatment for BPO, demonstrating clinically marked improvements in urinary function and quality of life at 12 months while preserving continence and sexual functions. However, it is not yet recommended by guidelines, and long-term outcomes and validation in larger cohorts remain essential.
引用
- Viitala A, Anttinen M, Mäkelä P, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study. BJU Int. 2025. PMID: 40432395. doi:10.1111/bju.16795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。